Literature DB >> 2432780

Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.

J M Feldman, T M O'Dorisio.   

Abstract

The plasma concentrations of neuropeptides (neurotensin, substance P, motilin, somatostatin, vasoactive intestinal peptide and gastrin-releasing peptide), the urinary excretion of 5-hydroxyindoleacetic acid and serotonin, and the platelet concentration of serotonin were compared in 133 patients who could be assigned to one of four groups. These groups were as follows: carcinoid tumors present; history of carcinoid tumors; miscellaneous tumors present; and non-tumor diseases. The test with the most sensitivity (i.e., patients with carcinoid tumors labeled positive) and the test with the most specificity (i.e., patients without carcinoid tumors labeled negative) for the presence of carcinoid tumors was determined. Urinary 5-hydroxyindoleacetic acid excretion had a sensitivity of 73 percent and a specificity of 100 percent; the plasma concentration of substance P had a sensitivity of 32 percent and a specificity of 85 percent; and the plasma concentration of neurotensin had a sensitivity of 41 percent and a specificity of 60 percent. Even when basal plasma concentrations of substance P and neurotensin were elevated, there was no additional increase of these neuropeptides prior to ethanol-induced facial flushing. Although measurements of plasma neuropeptide levels may be helpful in occasional patients with carcinoid tumors, it is concluded that measurements of serotonin overproduction--such as 5-hydroxyindoleacetic acid excretion--are of more general value.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2432780     DOI: 10.1016/0002-9343(86)90583-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  25 in total

Review 1.  Tubulovillous adenoma of the duodenum: a new etiology for flushing and urinary 5-HIAA elevation.

Authors:  S A Betchen; M Cirigliano; E E Furth; D Broussard; M Grippi; G R Lichtenstein
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

2.  Occult retroperitoneal carcinoid tumor with flushing and solitary lung metastasis.

Authors:  J A Jackson; H D Shipman
Journal:  West J Med       Date:  1989-10

Review 3.  Principles of diagnosis and management of neuroendocrine tumours.

Authors:  Michael J Raphael; David L Chan; Calvin Law; Simron Singh
Journal:  CMAJ       Date:  2017-03-13       Impact factor: 8.262

4.  Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital.

Authors:  Shridhar S Dronamraju; Vickram B Joypaul
Journal:  J Gastrointest Oncol       Date:  2012-06

Review 5.  Flushing in (neuro)endocrinology.

Authors:  Fady Hannah-Shmouni; Constantine A Stratakis; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 6.  Consensus on biomarkers for neuroendocrine tumour disease.

Authors:  Kjell Oberg; Irvin M Modlin; Wouter De Herder; Marianne Pavel; David Klimstra; Andrea Frilling; David C Metz; Anthony Heaney; Dik Kwekkeboom; Jonathan Strosberg; Timothy Meyer; Steven F Moss; Kay Washington; Edward Wolin; Eric Liu; James Goldenring
Journal:  Lancet Oncol       Date:  2015-09       Impact factor: 41.316

7.  Asymptomatic Ileal Neuroendocrine "Carcinoid" Tumor Incidentally Diagnosed on Colorectal Cancer Screening Colonoscopy: Does Routine TI Intubation Matter?

Authors:  Ali Zakaria; Lynna Alnimer; Gregory Byrd; Marc Piper; Michael Raphael; Bradley Warren; Michael Piper
Journal:  Case Rep Gastrointest Med       Date:  2021-02-03

8.  Determination of urinary 5-hydroxyindoleacetic acid as a metabolomics in gastric cancer.

Authors:  Maral Mokhtari; Amin Rezaei; Ali Ghasemi
Journal:  J Gastrointest Cancer       Date:  2015-06

Review 9.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

Review 10.  Carcinoid tumors.

Authors:  Scott N Pinchot; Kyle Holen; Rebecca S Sippel; Herbert Chen
Journal:  Oncologist       Date:  2008-12-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.